类风湿关节炎患者中不同生物制剂的新发银屑病风险特征
基于德国RABBIT登记研究,分析类风湿关节炎患者使用不同生物制剂或传统合成DMARDs后新发及复发银屑病的发生率和风险因素。结果显示TNFi暴露者新发银屑病风险显著高于csDMARDs,甲氨蝶呤可降低风险,女性及吸烟增加风险;有银屑病病史者复发事件罕见。
要点
- TNFi暴露者新发银屑病发生率显著高于csDMARDs(IR 3.04 vs 0.65/1000患者年)。
- 甲氨蝶呤联合治疗可降低新发银屑病风险(HR 0.5),女性和吸烟增加风险。
- 有银屑病病史者生物制剂相关复发事件罕见,但TNFi、阿巴西普和利妥昔单抗复发率高于csDMARDs。
核心结论
- TNFi暴露较csDMARDs增加新发银屑病风险,但总体风险低且事件通常不严重。
- TNFi联合甲氨蝶呤可能降低新发银屑病风险。
- 有银屑病病史的患者中,生物制剂相关复发事件罕见。
研究设计与样本
- 德国生物制剂登记RABBIT中无银屑病病史的RA患者14525例和有银屑病病史的375例分别分析。
- 所有至2017年10月报告的首次银屑病事件归因于前3个月的治疗。
- 计算粗发生率(每1000患者年),并用Cox回归(有无逆概率加权)调整适应证混杂。
主要发现
- 共报告117例新发和37例复发银屑病事件。
- TNFi暴露者新发银屑病粗发生率IR=3.04/1000患者年,显著高于csDMARDs仅暴露者IR=0.65。
- 阿巴西普、利妥昔单抗和托珠单抗的IR与csDMARDs无显著差异。
- 调整后Cox回归证实TNFi风险更高;女性HR=1.7、吸烟HR=2.1与新发银屑病显著相关,甲氨蝶呤降低风险HR=0.5。
- 复发银屑病中,TNFi、阿巴西普和利妥昔单抗的IR显著高于csDMARDs。
关键数值与推荐
- 新发银屑病粗发生率:TNFi 3.04/1000患者年 vs csDMARDs 0.65/1000患者年。
- 新发银屑病风险因素:女性HR=1.7,吸烟HR=2.1,甲氨蝶呤HR=0.5。
- 复发银屑病:TNFi、阿巴西普和利妥昔单抗的IR显著高于csDMARDs。
临床怎么用
- RA患者使用TNFi时应关注新发银屑病风险,尤其女性和吸烟者。
- TNFi联合甲氨蝶呤可能降低新发银屑病风险。
- 有银屑病病史者使用生物制剂时复发风险罕见,但仍需监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate rates and risk factors for incident and recurrent psoriasis in rheumatoid arthritis (RA) patients treated with different biologic (b) and conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs). METHODS: RA patients enrolled in the German biologics register RABBIT without (n = 14,525) or with a history of psoriasis (n = 375) were analyzed separately. All first events of psoriasis reported until October 2017 were assigned to the treatments prescribed in the previous 3 months. Crude incidence rates (IR) of psoriasis were calculated per 1000 patient-years. To investigate risk factors for psoriasis, cox regressions with and without inverse probability weights were applied to adjust for confounding by indication. RESULTS: 117 incident and 37 recurrent psoriatic events were reported. Patients exposed to TNFi had a significantly higher incidence rate (IR = 3.04/1,000 PY) than those exposed to csDMARDs only (IR = 0.65), whereas IRs for abatacept, rituximab and tocilizumab did not differ significantly from csDMARDs. Adjusted Cox regression confirmed a higher risk for TNFi. Female sex (HR: 1.7) and smoking (HR: 2.1) were significantly associated with incident psoriasis while methotrexate decreased the risk (HR: 0.5). For recurrent psoriasis, IRs for TNFi, abatacept and rituximab were significantly higher than for csDMARDs. CONCLUSIONS: Our data confirm a previously observed increased risk of incident psoriasis in patients exposed to TNFi compared to csDMARDs. However, the overall risk is low and the event is usually non-serious. Comedication of TNFi with methotrexate seems to lower the risk of incident psoriasis. In patients with a history of psoriasis, recurrence as adverse event is rare.
引用
- Baganz L, Listing J, Kekow J, et al. Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019. PMID: 31350056. doi:10.1016/j.semarthrit.2019.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。